A Prospective, Open-labeled, Clinical Study to evaluate the efficacy and safety of Depiklen for the treatment of hyper-pigmentation disorders in adults

Sante Mernaud Pharmaceuticals Pvt Ltd0 个研究点目标入组 24 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Males and females of age group 18-60 years
•Subjects who are willing to give written informed consent.
•Subjects with Fitzpatrick Skin types II to IV
•Subjects with hyper pigmentation disorders such as Melasma and lentigo (mild to moderate).
•Patient is willing and able to comply with all trial requirements

•Having major treatment, including topical hydroquinone or tretinoin, cryotherapy, electro-surgery, trichloroacetic acid application, laser or intense pulsed light, in the 3 months before the beginning of the study
•Past history of allergy to whitening cosmetic products
•Past history of atopic dermatitis
•Habit of going to the tanning salon or frequent sun exposure longer than 4 hours per day
•Present history of mental diseases
•Previous participation in a clinical trial within 6 months.

发起方

Sante Mernaud Pharmaceuticals Pvt Ltd